4-Methylthioamphetamine (4-MTA) is a designer drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic highly selective serotonin releasing agent (SSRA) in animals. It is distantly related to several other SSRAs including MMAI MDAI and MDMAI.
This page contains content from the copyrighted Wikipedia article "4-Methylthioamphetamine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
